Abstract Number: 0118 • ACR Convergence 2023
Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort
Background/Purpose: Physical performance is often not measured in clinical settings, despite its association with increased risk of disability, loss of independence, and mortality. Here, we…Abstract Number: 0183 • ACR Convergence 2023
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Background/Purpose: Despite greater prevalence of lupus among diverse, racial and ethnic minority populations, marked gaps exist between populations affected by lupus and those enrolled in…Abstract Number: 0462 • ACR Convergence 2023
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Background/Purpose: Breastfeeding in systemic lupus erythematosus (SLE) has received little attention and the limited data available suggest that women with SLE have lower breastfeeding rates…Abstract Number: 0554 • ACR Convergence 2023
A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked by varied disease activity, underscored by complex immune dysregulation, including altered immune mediators and…Abstract Number: 0571 • ACR Convergence 2023
A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test
Background/Purpose: A positive ANA (ANA-POS) test is present in almost all patients with SLE and is also frequently present in other autoimmune (AI) diseases and…Abstract Number: 0589 • ACR Convergence 2023
A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE
Background/Purpose: We have shown that serum IgA2 anti-dsDNA antibody levels is a biomarker of response to belimumab after rituximab in SLE (BEAT-lupus trial) (1). We…Abstract Number: 0608 • ACR Convergence 2023
Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…Abstract Number: 0847 • ACR Convergence 2023
Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus
Background/Purpose: Elevated IFN activity is observed in a subset of lupus subjects suggesting that those with higher levels of IRGs may benefit from interferon targeted…Abstract Number: 0902 • ACR Convergence 2023
Neutrophils in Systemic Lupus Erythematosus Demonstrate Heterogeneity Based on Sex
Background/Purpose: Sex differences in the immune system may contribute to o an increased incidence of autoimmunity in women and an increased susceptibility to infection and…Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…Abstract Number: 1094 • ACR Convergence 2023
“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity…Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…Abstract Number: 1446 • ACR Convergence 2023
Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database
Background/Purpose: The prevalence of depression and associated factors in systemic lupus erythematosus (SLE) are not well known and there are no longitudinal studies addressing this…Abstract Number: 1463 • ACR Convergence 2023
Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus
Background/Purpose: The purpose of this study was to investigate factors associated with objective cognitive impairment in patients diagnosed with Systemic Lupus Erythematous (SLE). Subjective complaints…Abstract Number: 1479 • ACR Convergence 2023
Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Background/Purpose: An impaired clearance of cervical human papillomavirus (HPV) related to inadequate immune responses may result in persistent infection and increase the risk to develop…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 150
- Next Page »